SS-31, or elamipretide, is researched for effects on mitochondrial function. The prescription product Forzinity received accelerated US approval to improve muscle strength in people with Barth syndrome weighing at least 30 kg.
Research focus: Mitochondrial function and Barth-syndrome muscle strength.
Choose a compound to open its research, documentation and calculator.
Forzinity: accelerated approval for muscle strength in Barth syndrome, weight at least 30 kg.
Official source ↗Elamipretide pharmacokinetics in the Forzinity development program.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗Community preparation guides describe BAC (bacteriostatic) water for lyophilized SS-31 research vials. This is separate from Forzinity, the approved elamipretide product supplied as a ready-made solution that is not reconstituted.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗The label instructions below apply to the named prescription products and their indications. A matching peptide name on another vial does not establish an equivalent formulation.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
A narrow approved indication; broad healthy-aging uses are a different research question.
Other names you may encounter: Elamipretide.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
For adults with eGFR <30 mL/minute who are not on dialysis: the label specifies 20 mg daily. Dialysis instructions are not established. This is not a general healthy-aging regimen.
MOTS-c followed as a separate phase in this account.
| When | Amount & frequency |
|---|---|
| Days 1–4 | 1 mg daily |
| Day 7 | 2 mg daily |
| Days 9–11 | 3 mg daily |
| Days 12–16 | 4 mg daily |
Only explicitly recoverable amounts are shown. Unlisted days are not assigned an inferred amount.
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Choose measurable goals such as day-to-day function, exercise tolerance or symptoms. A cellular biomarker is different from a demonstrated improvement in health or lifespan.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.